The estimated Net Worth of Jeffrey Allen Bailey is at least $440 Thousand dollars as of 9 March 2022. Mr. Bailey owns over 5,333 units of Aileron Therapeutics Inc stock worth over $302,783 and over the last 9 years he sold ALRN stock worth over $43,500. In addition, he makes $93,720 as Chairman of the Board at Aileron Therapeutics Inc.
Jeffrey has made over 13 trades of the Aileron Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 5,333 units of ALRN stock worth $15,359 on 9 March 2022.
The largest trade he's ever made was buying 55,000 units of Aileron Therapeutics Inc stock on 14 November 2019 worth over $28,050. On average, Jeffrey trades about 6,979 units every 29 days since 2015. As of 9 March 2022 he still owns at least 105,133 units of Aileron Therapeutics Inc stock.
You can see the complete history of Mr. Bailey stock trades at the bottom of the page.
Jeffrey A. Bailey serves as Chairman of the Board of the Company. Mr. Bailey has served as chief executive officer and director of IlluminOss Medical, Inc., a medical device company. From December 2015 until March 2017, Mr. Bailey served as chair and chief executive officer of Neurovance, Inc., a biotechnology firm acquired by Otsuka Pharmaceutical in 2017. Previously, from January 2013 through June 2015, Mr. Bailey served as president and chief executive officer and as a director of Lantheus Medical Imaging, Inc., a public medical diagnostic company. Prior to 2013, Mr. Bailey held various leadership positions with several public and private pharmaceutical and medical device companies, including operating unit president at Novartis Pharmaceuticals, a multinational pharmaceutical company, and a 22-year career with Johnson & Johnson, multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company (including Janssen Pharmaceutica NV). Mr. Bailey has served as a director of Madison Vaccines, Inc. since October 2017 and BioDelivery Sciences International, Inc. since March 2020. Mr. Bailey received a B.S. from Rutgers University.
As the Chairman of the Board of Aileron Therapeutics Inc, the total compensation of Jeffrey Bailey at Aileron Therapeutics Inc is $93,720. There are 6 executives at Aileron Therapeutics Inc getting paid more, with Manuel Aivado having the highest compensation of $1,178,060.
Jeffrey Bailey is 58, he's been the Chairman of the Board of Aileron Therapeutics Inc since 2018. There are 3 older and 9 younger executives at Aileron Therapeutics Inc. The oldest executive at Aileron Therapeutics Inc is Nolan Sigal, 70, who is the Independent Director.
Jeffrey's mailing address filed with the SEC is #140, 14315-118 AVENUE, , EDMONTON, A0, T5L 4S6.
Over the last 14 years, insiders at Aileron Therapeutics Inc have traded over $6,473,296 worth of Aileron Therapeutics Inc stock and bought 16,658,005 units worth $51,661,886 . The most active insiders traders include Muneer A Satter, Bioventures Ltd Novartis Ag..., and Armen Shanafelt. On average, Aileron Therapeutics Inc executives and independent directors trade stock every 77 days with the average trade being worth of $908,853. The most recent stock trade was executed by Of Texas/Texas Am Investmen... on 14 June 2024, trading 6,607 units of ALRN stock currently worth $21,539.
aileron is the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases. our lead product candidate, alrn-6924, which is being evaluated in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting both of the primary p53 suppressor proteins mdmx and mdm2. the p53 protein, often referred to as the “guardian of the genome,” is known for its central role in preventing cancer initiation and progression, and its inactivation is essential for the formation of virtually all cancers. we believe that alrn-6924 is the first and only product candidate in clinical development that can inhibit both mdmx and mdm2, which we believe, based on published data and our preliminary clinical results, are equally important in restoring p53 function as the body’s first line of defense against cancer. based on preclinical data and preliminary evidence of safety and anti-tumor activity in our ongoing clinical trials, we believe there may be a sig
Aileron Therapeutics Inc executives and other stock owners filed with the SEC include: